-

12:26:46 PM

LIVE Real Time VERU Stock Market News

VERU - Veru Inc

04/21/21 8:30 AM

Nasdaq : VERU

Veru Announces Presentation of Phase 2 Study of Enobosarm -- a Selective Androgen Receptor Targeting Agent in Metastatic AR+ER+HER2- Breast Cancer at 2021 ESMO Breast Cancer Congress

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that clinical results from the Phase 2 clinical study of enobosarm, a selective

RHEA-AI

neutral

03/09/21 8:30 AM

Nasdaq : VERU

Veru to Present at the Oppenheimer 31st Annual Healthcare Conference

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the Oppenheimer 31 st Annual Healthcare

RHEA-AI

neutral

03/08/21 8:30 AM

Nasdaq : VERU

Veru Exploring Strategic Alternatives for its Legacy Female Health Business

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer, today announced that it has engaged Morgan Stanley & Co. LLC as a financial advisor to

RHEA-AI

neutral

03/02/21 8:30 AM

Nasdaq : VERU

Veru to Participate in Fireside Chat at the H.C. Wainwright Global Life Sciences Conference

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright Global

RHEA-AI

neutral

03/01/21 8:30 AM

Nasdaq : VERU

Veru Receives FDA Agreement to Advance VERU-111 into Phase 3 Study in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)

- Veru completes expedited end of Phase 2 trial meeting with FDA - - FDA agrees that Phase 2 clinical findings suggest a clinically meaningful benefit for the use of VERU-111 in hospitalized COVID-19 patients at high risk for ARDS - - FDA agrees to advance VERU-111 into Phase 3 clinical study in

RHEA-AI

positive

02/23/21 8:30 AM

Nasdaq : VERU

Veru Submits New Drug Application for Proprietary TADFIN for BPH

RHEA-AI

neutral

02/17/21 9:30 PM

Nasdaq : VERU

Veru Announces Pricing of Public Offering of Common Stock

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, announced today the pricing of an underwritten public offering of 6,451,613 shares of its common

RHEA-AI

neutral

02/17/21 4:01 PM

Nasdaq : VERU

Veru Announces Proposed Public Offering of Common Stock

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, announced today that it intends to offer and sell, subject to market conditions, shares of its

RHEA-AI

neutral

02/10/21 6:30 AM

Nasdaq : VERU

Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 First Quarter

Company Reports

RHEA-AI

neutral

02/08/21 7:30 AM

Nasdaq : VERU

Veru Reports Positive Phase 2 Clinical Results of VERU-111 in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

- Potential for two-pronged action against COVID-19 as an antiviral and anti-inflammatory agent supported by Phase 2 clinical study results - - Primary efficacy endpoint in hospitalized patients shows VERU-111 treatment had statistically significant 81% relative reduction in death or respiratory

RHEA-AI

neutral